HIV drug could be made for just $40 a year for every patient
Generic version of a drug already on the market, which can suppress and prevent HIV, would still yield 30% profit if the current price was slashed, researchers say
Supported by
OSF (Fair Access)
About this content
Kat Lay, Global health correspondent, in Munich
Tue 23 Jul 2024 04.00 EDT
Share
A new drug described as “the closest we have ever been to an HIV vaccine” could cost $40 (£31) a year for every patient, a thousand times less than its current price, new research suggests.
Lenacapavir , sold as Sunlenca by US pharmaceutical giant Gilead, currently costs $42,250 for the first year. The company is being urged to make it available at a thousand times less than that price worldwide.
UNAids said it could “herald a breakthrough for HIV prevention” if the drug was available “rapidly and affordably”.
Given by injection every six months, lenacapavir can prevent infection and suppress HIV in people who are already infected.
In a trial, the drug offered 100% protection to more than 5,000 women in South Africa and Uganda, according to results announced by Gilead last month.
Lenacapavir is currently licensed for treatment, not prevention.
In a study presented at the 25th international Aids conference in Munich on Tuesday, experts calculated that the minimum price for mass production of a generic version, based on the costs of lenacapavir’s ingredients and manufacturing, and allowing for 30% profit, was $40 a year , assuming 10 million people used it annually. In the long-term, 60 million people would probably need to take the drug preventatively to lower HIV levels significantly, they said.
https://www.theguardian.com/global-development/article/2024/jul/23/hiv-aids-prevention-vaccine-lenacapavir-sunlenca-pharmaceuticals-gilead-generic-licensing 